Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone is a hydroxy-1,4-naphthoquinone analogue of ubiqu...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorillo, Marco, Lamb, Rebecca, Tanowitz, Herbert B., Mutti, Luciano, Krstic-Demonacos, Marija, Cappello, Anna Rita, Martinez-Outschoorn, Ubaldo E., Sotgia, Federica, Lisanti, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085139/
https://www.ncbi.nlm.nih.gov/pubmed/27136895
http://dx.doi.org/10.18632/oncotarget.9122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085139/
https://www.ncbi.nlm.nih.gov/pubmed/27136895
http://dx.doi.org/10.18632/oncotarget.9122

Ejemplares similares